AnaptysBio Inc. priced an underwritten public offering of 3 million common shares at $68.50 apiece for expected gross proceeds of $205.5 million.

The company granted underwriters an option to buy up to an additional 450,000 shares.

The offering is expected to close Oct. 17, subject to customary closing conditions.

Credit Suisse, Jefferies and Stifel are acting as joint book-running managers for the offering, with Wedbush PacGrow, Baird and SunTrust Robinson Humphrey as co-managers.